In The News

“From a political standpoint, it is foolish to push importation. If deaths occur, the politician who promoted it will take the blame,” said Merrill Matthews, a resident scholar with the Institute for Policy Innovation.

The Iranian government is rattling sabers once again. In years past those tensions would have sent world oil markets into a panic. Not so this time around. 

Sen. John Cornyn's legislation that attempts to address problems he sees with the patent protections afforded to American drug companies overreaches and would limit the ability of pharmaceutical firms to develop and improve medicines. 

Bartlett D. Cleland, research fellow with the Institute for Policy Innovation, said the FCC “needs to establish a continuous supply of spectrum via auctions, on a schedule that will provide a regular flow of low, mid and high bands of spectrum. They must keep unlicensed bands open and available as well.”

Most House Republicans have committed in one way or another to not raise taxes, but this seems to be a session characterized by commitments broken and principles betrayed.

It is difficult to see why those guilty of heinous crimes should retain their right to vote.

A new Health and Human Services rule requiring pharmaceutical companies to disclose list prices for medications in commercial advertisements is unlikely to boost price transparency for consumers. In fact, it may create even more confusion.

If lawmakers want to cut drug spending without leaving patients in the lurch, they’d be wise to foster more competition in the drug marketplace. Price controls are more about limiting access than price.

"We have no objection in principle to a revenue neutral tax swap that reduces property taxes by increasing consumption taxes, especially since consumption taxes are a less harmful form of taxation," said IPI president Tom Giovanetti. "A revenue neutral tax swap is not a tax increase. The devil is in the details, however."